A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival.

Kurumaddali, Abhinav; Salem, Ahmed Hamed; Agarwal, Suresh K

Kurumaddali, Abhinav; Salem, Ahmed Hamed; Agarwal, Suresh K.

Afiliação

Kurumaddali A; Department of Pharmaceutics, University of Florida, Gainesville, FL.
Salem AH; Abbvie, Inc., North Chicago, IL.
Agarwal SK; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

J Cancer ; 10(22): 5427-5433, 2019.

Article em En | MEDLINE | ID: mdl-31632487

Palavras-chave

Myelodysplastic syndrome; azacitidine; overall survival; response rates; surrogate endpoints; treatment-naive

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google